Organoclick AB (ORGC) fair value: what the stock is really worth
We calculate from audited financials what Organoclick AB is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Valuation from Jul 15, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
Watch Organoclick AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.
How to read this chart
60‑month range kr 0.2200 – kr 12.85 · fair‑value band kr 0.0400 – kr 0.0800 · the kr 0.2500 price screens above the kr 0.0600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Jul 15, 2026.
Follow Organoclick in your weekly email
Every Wednesday you see whether Organoclick is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OrganoClick AB (publ), a green chemical company, develops and markets biobased and biodegradable chemical products and material technologies for the treatment of nonwoven, technical textile, and wood in Sweden, Other Nordics, the Rest of Europe, Asia, North America, and Oceania.
Show more
OrganoClick AB (publ), a green chemical company, develops and markets biobased and biodegradable chemical products and material technologies for the treatment of nonwoven, technical textile, and wood in Sweden, Other Nordics, the Rest of Europe, Asia, North America, and Oceania. The company offers OrganoTex, a biodegradable and durable water repellent (DWR) technology for textile and shoe impregnation, and detergents; OrganoWood, a timber product and a wood preservative technology that provides wood with protection against decay and termites; and OrganoComp, a bio composite that is used for 3D forming. It also provides BIOkleen maintenance and cleaning products, as well as paint removal products; OC-BioBinder, a biobased and biodegradable binder used in nonwoven and technical textiles; and OC-AquaSil Tex, a biodegradable hydrophobing product used in nonwovens, specialty papers, and technical textiles. The company sells its products through a network of retailers. It serves the nonwoven, paper, textile, wood treatment, and construction industries, as well as consumers and homeowners. OrganoClick AB (publ) was incorporated in 2006 and is headquartered in Täby, Sweden.
Stock analysis
Organoclick AB (ORGC) currently trades at kr 0.2500, while our model-based Fair Value estimate is kr 0.0600, implying the stock looks roughly 316.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 89/100, which puts the evidence level at low.
Scenario range: kr 0.0400 (bear) to kr 0.0800 (bull), the price of kr 0.2500 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Basic Materials sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Organoclick AB reported revenue of 106M SEK in FY2025 versus 110M SEK in FY2021, a compound −0.9%/yr. Reported net income was −36.4M SEK in FY2025.
Key figures
Market cap 81.7M SEK (≈ $8.2M) · P/S ratio 0.83 · EPS (TTM) kr −0.3400 · Net margin −34.3% · Return on equity −137% · Return on assets (EBIT) −15.4% · Operating margin 1.2% · Revenue (TTM) 98.2M SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).
What moves the price
The share trades about 87% below its 52-week high and 14% above its 52-week low.
For context, the median of 10 Basic Materials peers we cover trades at −40% fair-value upside, at −76%, ORGC screens richer than that median.
Fair Value models
Bear kr 0.0400Fair Value kr 0.0600Bull kr 0.0800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.9/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−16.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17.9% (2020) → −29.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 713 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score22 · Bottom 25%
Fair Value upside−77% · Bottom 25%
Profitability
Return on assets−9% · Bottom 25%
Net margin (TTM)−35% · Bottom 25%
Operating margin (TTM)1% · Bottom 25%
Growth and dividend
Revenue growth−23% · Bottom 25%
Balance sheet
Debt / equity0.23× · Above median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/B0.54× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.08× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 21
PAST (return on equity)0· sector 23
HEALTH (low debt)89· sector 95
DIVIDEND (yield)0· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Organoclick AB Fair Value". https://www.fairvalue-calculator.com/stock/ORGC
Frequently asked questions
Is Organoclick AB (ORGC) overvalued or undervalued?
As of Jul 15, 2026, our model estimates a fair value of kr 0.0600 versus a price of kr 0.2500, about −76% upside (overvalued).
What is the fair value of ORGC?
Our model-based fair value for Organoclick AB is kr 0.0600 (as of Jul 15, 2026), built from audited fundamentals. The current price: kr 0.2500.
What is the quality score of ORGC?
Organoclick AB has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Organoclick AB (ORGC)?
Our model-based price target is the fair value of kr 0.0600 (as of Jul 15, 2026) from 1 valuation models. Cautious scenario kr 0.0400, optimistic scenario kr 0.0800. It is a calculation from audited fundamentals, not an analyst target.
What is the Organoclick AB stock forecast for 2026?
Our models put fair value at kr 0.0600, about −76% upside versus a price of kr 0.2500 (overvalued). Cautious scenario kr 0.0400, optimistic scenario kr 0.0800. The calculation is refreshed regularly with new filings.
What is the revenue of Organoclick AB (ORGC)?
Organoclick AB reported trailing-twelve-month revenue of about 98.2M SEK (latest available figure, as of Jul 15, 2026).
What is the intrinsic value of Organoclick AB (ORGC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Organoclick AB it is kr 0.0600 per share (as of Jul 15, 2026), against a price of kr 0.2500. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Organoclick AB stock overvalued or undervalued in 2026?
As of Jul 15, 2026, ORGC trades above its calculated fair value: price kr 0.2500, fair value kr 0.0600, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ORGC?
No. The price is what the market pays today (kr 0.2500); the fair value is what the company's own numbers justify (kr 0.0600). For Organoclick AB the two are kr 0.1900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Organoclick AB worth?
The market values Organoclick AB at about 81.7M SEK (market capitalisation, as of Jul 15, 2026). Per share that is kr 0.2500; our models calculate a fair value of kr 0.0600 per share.
What do the bullish and bearish scenarios say about ORGC?
Our models span a range for Organoclick AB: cautious scenario kr 0.0400, base kr 0.0600, optimistic kr 0.0800 per share (as of Jul 15, 2026, price kr 0.2500). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Organoclick AB (ORGC)?
Balance-sheet figures for Organoclick AB (as of Jul 15, 2026): return on equity −136.5%, debt of 0.23 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is ORGC from its 52-week high?
Organoclick AB trades at kr 0.2500, about 87% below its 52-week high of kr 1.88 and 14% above the low of kr 0.2200 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.0600 is for.
Which stocks are comparable to Organoclick AB?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Organoclick AB stock attractive at the current price?
The data as of Jul 15, 2026: price kr 0.2500, calculated fair value kr 0.0600 (−76%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ORGC calculated?
We run Organoclick AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.0600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Organoclick AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Organoclick AB (ORGC)?
The closing price on Sep 24, 2026 was kr 0.2500. Our model-based fair value is kr 0.0600, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Organoclick AB right now?
The price sits above even our optimistic bull case (kr 0.0800). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.0400 to kr 0.0800) leaves room in how you read the outcome.
Key figures of Organoclick AB
How large is the market capitalisation of Organoclick AB (ORGC)?
The market capitalisation of Organoclick AB is 81.7M SEK (≈ $8.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Organoclick AB (ORGC)?
The price-to-sales ratio of Organoclick AB is 0.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Organoclick AB (ORGC)?
Earnings per share at Organoclick AB are kr −0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Organoclick AB (ORGC)?
The net margin of Organoclick AB is −34.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Organoclick AB (ORGC)?
The return on equity (ROE) of Organoclick AB is −137% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Organoclick AB (ORGC)?
On an EBIT basis the return on assets of Organoclick AB is −15.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Organoclick AB (ORGC)?
The operating margin of Organoclick AB is 1.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Organoclick AB (ORGC)?
Revenue at Organoclick AB is growing −22.7% versus a year earlier (3y avg −2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Organoclick AB (ORGC) generate?
The free cash flow of Organoclick AB is −10.5M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Organoclick AB (ORGC) carry?
The net debt of Organoclick AB is 75.1M SEK (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Organoclick AB in the live analysis
One click puts Organoclick AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
